Christine E. Hallgreen

World Health Organization - Denmark — Denmark

Economics, Econometrics and Finance · Social Sciences

14h-index600citations47works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(16), Pharmaceutical Economics and Policy(10), Pharmaceutical studies and practices(7), Meta-analysis and systematic reviews(6), Patient-Provider Communication in Healthcare(4)

Publications47 total

The evolution of SSRI research: trajectories of knowledge domains across four decades
BMC Psychiatry·2026Open Access
Digitalizing Risk Minimization Measures in EU: Explorative Co-design Workshops with Expert Stakeholders
Therapeutic Innovation & Regulatory Science·2025
Early adoption patterns of the recombinant zoster vaccine: real-world versus clinical trial populations
Infectious Diseases·2025Open Access
Sexual Dysfunction in Male Patients After Initiating Treatment with Antidepressants
Drug Safety·2025· 1 citedOpen Access
Data - Pivotal Clinical Evidence Supporting European Centralised Approvals of New Active Substances between 2023 and 2024
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Data - Pivotal Clinical Evidence Supporting European Centralised Approvals of New Active Substances between 2023 and 2024
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences
Therapeutic Advances in Drug Safety·2025Open Access
Populations Addressed in Vaccines Approved via the European Medicines Agency
Clinical Pharmacology & Therapeutics·2025· 1 citedOpen Access
Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC): A Quantitative Review of the Post-Authorisation Safety Evaluation of Antidiabetic Drugs from 2012 to 2022
Drug Safety·2025· 2 citedOpen Access
The impact of operational trial approaches on representativeness: Comparison of decentralized clinical trial participants, conventional trial participants, and patients in daily practice
Drug Discovery Today·2025· 4 citedOpen Access
The life cycle of vaccines evaluated by the European Medicines Agency
Vaccine·2024· 3 citedOpen Access
Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis
Frontiers in Pharmacology·2023· 5 citedOpen Access
Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study
Drug Safety·2023· 24 citedOpen Access
Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan
Biological and Pharmaceutical Bulletin·2023· 3 citedOpen Access
Mandatory requirements for pediatric drug development in the EU and the US for novel drugs—A comparative study
Frontiers in Medicine·2022· 5 citedOpen Access
Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends
Zenodo (CERN European Organization for Nuclear Research)·2022· 2 citedOpen Access
New Information on Old Medicinal Products: A Cross-Sectional Analysis of Guidance for Paediatric Use for Substances on the European Priority List of Off-Patent Medicinal Products
Pediatric Drugs·2022Open Access
Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross‐Sectional Analysis of Centralized Procedures in the European Union 2010–2020
Clinical Pharmacology & Therapeutics·2022· 16 citedOpen Access
Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study
Drug Safety·2022· 3 citedOpen Access
Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US
PLoS ONE·2022· 4 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Marie L. De Bruin(11), Shahrul Mt‐Isa(9), Alain Micaleff(8), Deborah Ashby(8), Lawrence D. Phillips(7), A Lieftucht(6), Morten Andersen(6), Débora Dalmas Gräf(6), Kimberley Hockley(5), Gerald Downey(5), Rebecca Noel(5), Helga Gardarsdóttir(5), Georgy Genov(4), Ioanna Tzoulaki(4), Diana Hughes(4), Ed Waddingham(4), Richard Hermann(4), Patrick C. Souverein(4), Helle Christiansen(4), Haoxin Le(4)